Stockreport

CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet

CARGO Therapeutics, Inc.  (CRGX) 
PDF Ongoing Phase 1 study informed dose selection for CARGO’s currently enrolling, potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) [Read more]